Antineoplaston Therapy in Treating Patients With Ependymoma

Stopped early · Phase 2

Conditions studied: Ependymoma

In brief

RATIONALE: Current therapies for patients with ependymoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of patients with ependymoma . PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on patients with ependymoma.

Key facts

Study ID

NCT00003479

Run by

Burzynski Research Institute

People needed

9

Starts

1966-07-01

Expected to finish

2000-10-01

Last updated by the study team

2022-02-23

Who can join

Age: 1 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Burzynski Clinic — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.